MetLife, Inc. (MET) is currently trading at $93.27. Based on 16 Wall Street analysts, the average target price is $96.63, implying a 3.6% upside. The consensus recommendation is BUY.

MET

MetLife, Inc.

FinancialsOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$93.27

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$86.00$106.00
Current $93.27
Median: $101.00Mean: $98.71Current: $93.27

Recent price target updates (latest 80)

  • TD CowenJul 22, 2026

    PT action: Raises

    $87.00 → $105.00

  • JP MorganJul 21, 2026

    PT action: Raises

    $96.00 → $106.00

  • Evercore ISI GroupJul 13, 2026

    PT action: Raises

    $96.00 → $103.00

  • Keefe, Bruyette & WoodsJul 13, 2026

    PT action: Raises

    $98.00 → $105.00

  • JefferiesJul 10, 2026

    PT action: Raises

    $97.00 → $103.00

  • Wells FargoJul 9, 2026

    PT action: Raises

    $95.00 → $101.00

  • MizuhoJul 9, 2026

    PT action: Raises

    $95.00 → $102.00

  • UBSJul 8, 2026

    PT action: Raises

    $102.00 → $105.00

  • BarclaysJul 7, 2026

    PT action: Raises

    $93.00 → $94.00

  • Morgan StanleyJul 6, 2026

    PT action: Raises

    $93.00 → $103.00

  • Piper SandlerJun 24, 2026

    PT action: Raises

    $86.00 → $90.00

  • Piper SandlerMay 26, 2026

    PT action: Raises

    $81.00 → $86.00

  • Morgan StanleyMay 21, 2026

    PT action: Raises

    $89.00 → $93.00

  • Keefe, Bruyette & WoodsMay 13, 2026

    PT action: Raises

    $87.00 → $98.00

  • JP MorganMay 12, 2026

    PT action: Raises

    $95.00 → $96.00

  • Wells FargoMay 12, 2026

    PT action: Raises

    $90.00 → $95.00

  • BarclaysMay 7, 2026

    PT action: Raises

    $89.00 → $93.00

  • B of A SecuritiesApr 14, 2026

    PT action: Lowers

    $103.00 → $99.00

  • MizuhoApr 13, 2026

    PT action: Lowers

    $100.00 → $93.00

  • Wells FargoApr 10, 2026

    PT action: Lowers

    $93.00 → $90.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$96.63

Based on 16 analysts

Analyst Recommendations

Buy (12)Hold (5)Sell (1)

Upside

+3.60%

Market Cap

$60.01B

Financial & Investment Metrics

Next Earnings Date
Aug 5, 2026D-14
P/E Ratio (TTM)18.04
Forward P/E8.49
P/B Ratio2.21
Dividend Yield2.54%
Return on Equity (ROE)13.01%
Operating Margin9.92%
Debt to Equity178.02
Beta (Volatility)0.78
52 Week Range$67.33 - $94.86
LowCurrent: $93.27High

Latest News

Daily editorial mentioning MET

Price target moves

Healthcare and Energy Dominate July 10 Price Target Revisions

As of the morning of July 10, 2026, the desks have been busy processing a wave of target adjustments across the S&P 500. While the volume of revisions remains elevated, sector-specific sentiment appears to be pulling in competing directions, particularly within the energy and healthcare spaces.

* RBC Capital was particularly active, lifting targets across UNH, ELV, and CVS. * Energy names like DVN and AR faced downward revisions from Truist Securities. * Goldman Sachs signaled a significant adjustment for NOW, lowering the target to 145.

Notable adjustments

The movement in the healthcare sector was sharp. RBC Capital pushed UnitedHealth (UNH) from 400 to 463, while Elevance Health (ELV) saw a move from 358 to 439. CVS Health (CVS) also saw a modest lift to 113 from 107. These adjustments arrive despite a broader caution elsewhere; for instance, Piper Sandler’s subtle trim to Regeneron (REGN), moving it from 855 to 854, suggests some analysts are finding limited room for further upside in high-priced biopharma.

In the energy patch, the outlook has taken a more defensive turn. Citigroup dialed back EOG Resources (EOG) to 141 from 147, and Truist Securities lowered its expectations for both Devon Energy (DVN) and Antero Resources (AR). DVN dropped from 66 to 61, while AR shifted from 56 to 52. These downward revisions contrast with the optimism seen in other corners of the market, such as UBS pushing TSLA up to 442 from 364.

Broader watchlist context

Financials were a mixed bag of activity. Wells Fargo opted to boost the targets for MetLife (MET) and Chubb (CB), moving them to 101 and 358 respectively, while simultaneously trimming Aon (AON) to 406. Perhaps most telling was the shift in sentiment toward Intercontinental Exchange (ICE), which Barclays moved down to 180 from 201.

The materials sector also saw some cooling. Goldman Sachs lowered Freeport-McMoRan (FCX) to 74 from 75, and RBC Capital reduced its target for Newmont (NEM) to 135 from 140. For a complete view of how these shifts compare to historical trends, see the full moves database. The disparity between these downward adjustments and the more aggressive moves in industrials—where GE was lifted to 430 by Susquehanna—highlights the fragmented nature of current analyst sentiment.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 2

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
6/1/2026DEBEL MARLENEOfficerSale at price 81.59 per share.21,312
5/12/2025PAPPAS BILLOfficerSale at price 80.49 per share.26,000

Frequently Asked Questions

Q. What is the current target price and upside for MET?

A. The current target price for MetLife, Inc. is $96.63, which implies a 3.6% upside from the current price of $93.27. This is based on the consensus of 16 Wall Street analysts.

Q. What is the current analyst recommendation for MET?

A. Currently, there are 4 Strong Buy, 8 Buy, 5 Hold, 0 Sell, and 1 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying MET stock recently?

A. Over the past 6 months, there have been 0 insider buys and 2 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Financials

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer